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Abstract
Motor vehicle collision (MVC) can trigger chronic widespread pain (CWP) development in 
vulnerable individuals. Whether such CWP typically develops via the evolution of pain from 
regional to widespread or via the early development of widespread pain with non-recovery is 
currently unknown. We evaluated the trajectory of CWP development (American College of 
Rheumatology criteria) among 948 European-American individuals who presented to the 
emergency department (ED) for care in the early aftermath of MVC. Pain extent was assessed in 
the ED and 6 weeks, 6 months, and 1 year after MVC on 100%, 91%, 89%, and 91% of 
participants, respectively. Individuals who reported prior CWP at the time of ED evaluation (n = 
53) were excluded. Trajectory modeling identified a two-group solution as optimal, with the Bayes 
Factor value (138) indicating strong model selection. Linear solution plots supported a non-
recovery model. While the number of body regions with pain in the non-CWP group steadily 
declined, the number of body regions with pain in the CWP trajectory group (192/895, 22%) 
remained relatively constant over time. These data support the hypothesis that individuals who 
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develop CWP after MVC develop widespread pain in the early aftermath of MVC which does not 
remit.
 1. Introduction
Population-based studies indicate that 11–13% of adults suffer from chronic widespread 
pain (CWP) [46], defined as pain on both the left and right side of the body, above and 
below the waist, and including the axial region [50]. These individuals experience 
substantial disability and reduced quality of life [11; 27]. The pathogenesis of CWP remains 
poorly understood [25; 28; 29; 35], and gaining a greater understanding of this disease is an 
important public health priority [19].
One known trigger of CWP is motor vehicle collision (MVC) [18; 22; 51; 52]; the natural 
history of CWP development after MVC is currently unknown. One common hypothesis is 
that chronic regional pain first develops and then progresses to CWP in vulnerable 
individuals [18; 23; 25; 46]. Another possibility is that in vulnerable individuals CWP 
develops in the early aftermath of MVC and persists [7; 18]. Accurately identifying the 
typical trajectory of CWP development after MVC is important both in order to gain insights 
into potential etiologic mechanisms and also to inform the design of future studies.
In this study, we examined the developmental trajectory of CWP among a cohort of 
individuals who presented to the emergency department (ED) for care after MVC and were 
followed prospectively for one year. Trajectory modeling was used to determine if either a 
progressive onset model of CWP development or an early onset/non-recovery model of 
CWP development provided a good fit to the data. Because evidence suggests that 
mechanisms related to stress-induced hyperalgesia play an important role in the 
pathogenesis of chronic pain after MVC (reviewed in [41]), and because such mechanisms 
are mediated by central neurobiological systems mechanisms with widespread effects and 
relatively early onset (reviewed in [41]), we hypothesized that CWP development would be 
characterized by a non-recovery rather than a progressive accrual model. In addition, we 
evaluated demographic characteristics of participants with and without CWP after MVC and 
co-morbid psychological and somatic symptoms in these groups.
 2. Methods
 2.1 Design and setting
This prospective longitudinal study enrolled patients presenting to the ED within 24 hours of 
MVC. Data were collected at eight EDs in four no-fault MVC litigation/insurance states, 
where litigation related to MVC is low, (Michigan, Massachusetts, New York, and Florida) 
between February 2009 and October 2011. Study participants were enrolled at research 
network ED sites and received an initial interview evaluation at the time of the ED visit. 
Follow-up assessments were performed at 6 weeks, 6 months, and one year. The study was 
approved by the institutional review boards of all participating hospitals, and each 
participant provided written informed consent. Complete information regarding study 
design, procedures, and methods has previously been described. [38]
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 2.2 Participant eligibility criteria and study sites
Patients ages 18 to 65 who presented to the ED within 24 hours after a MVC and were 
unlikely to require hospitalization were screened for eligibility. Patients who were admitted 
to the hospital, had fractures other than phalangeal fractures, had more than 4 lacerations 
requiring sutures or a single laceration more than 20 cm in length, or had intracranial or 
spinal injuries were excluded. Spinal injury was defined by the presence of a fracture, 
dislocation, or new neurologic deficit. Enrollment was also limited to non-Hispanic whites 
(the most common ethnicity at study sites) because the study included the collection of 
genetic data and genetic analyses are potentially biased by population stratification.[16] 
Patients who were not alert and oriented were also excluded, as were pregnant patients, 
prisoners (due to risk of coercion [5]), patients unable to read and understand English, 
patients taking a β-adrenoreceptor antagonist (due to concern for confounding because β-
adrenergic mechanisms have been implicated in chronic pain development [32]), or patients 
taking opioids above a total daily dose of 20 mg of oral morphine or equivalent.
 2.3 Study procedures
Eligible and consenting participants completed ED interview evaluations regarding pre-
MVC health status, the details of the MVC, and current symptoms. Interviews were 
conducted by research staff at the time of the ED visit using a web-based survey with 
explicit definitions of variables. Before enrolling patients in the ED, each research staff 
member completed a study training module followed by an interview with a standardized 
mock ED patient. Comparison of mock ED patient data across research staff demonstrated 
an error rate of 1.3%. Injury characteristics and medications administered in the ED were 
obtained by data extraction from the ED medical record. Study personnel extracted 
participant injury data from the participant’s medical record using a standardized web-based 
data extraction form with explicit definitions of all variables. All aspects of the emergency 
medical record, including physician notes, nursing notes, and physical orders were used for 
completion. Information obtained included the presence and location of any fractures, 
lacerations, contusions, avulsions, and abrasions. Injury information was used to generate 
Abbreviated Injury Severity Scores [1]. Six weeks, six months and one year after the MVC, 
participants completed a follow up interview online, by telephone, or via mail. Regardless of 
follow up type, survey content was identical. Participants were compensated $80 for 
completing the ED interview, $60 for completing the 6 week interview, $65 for completing 
the 6 month interview and $70 for completing the 1 year interview.
 2.4 Measures
A number of measures were used to assess health status prior to MVC and symptoms in the 
ED. Complete study measures are described in full elsewhere.[38]
 2.4.1 Participant demographics—Participant demographic characteristics (including 
age, gender, income, height, weight, and educational attainment) were obtained from the ED 
medical record and from participant self-report.
 2.4.2 Pain assessments and pain outcome definitions—Pain extent during the 
month prior to the MVC and in the ED were both assessed at the time of ED evaluation; pain 
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extent six weeks, six months and one year after MVC was assessed at the respective 
timepoint. Pain extent was assessed in 19 discrete body regions evaluated in the regional 
pain scale[49] and in the head region. Widespread pain (WP) was defined according to the 
American College of Rheumatology (ACR) 1990 criteria [50]. In each body region in which 
the participant reported pain, average pain severity was assessed using a verbal 0 to 10 
numeric rating scale (NRS). Verbal scores have advantages in acute care settings, and 
verbally administered NRSs have been validated as highly correlated with visual analogue 
scale scores. [34] Regional pain was defined by the presence of one or more body regions 
with a NRS score greater than zero. Number of body regions with pain at each timepoint 
was defined as the number of body regions with a NRS score greater than zero.
 2.4.3 Psychological symptoms—Distress was assessed using the Peritraumatic 
Distress Inventory (PDI). This measure has high internal consistency (0.75–0.76) and test-
retest reliability (0.74).[10] A PDI cut-off score of ≥23 was used to define marked distress 
symptoms ("distress").[36] Post-traumatic stress disorder symptoms were measured at 6-
week, 6-month, and 1-year timepoints using the Impact of Events Scale – Revised (IES-R)
[47]. Depressive symptoms during the week prior to the MVC were assessed using the 
Center for Epidemiologic Studies Depression Scale (CES-D).[40] Based on previous 
evidence, CES-D scores between 16 and 25 were defined as mild depressive symptoms and 
scores greater than or equal to 26 were defined as severe depressive symptoms.[48; 53]
 2.4.4 Somatic symptoms—Somatic symptoms during the past month were assessed at 
the time of the ED assessment and via telephone or web-based questionnaire six weeks, six 
months, and one year after MVC. The somatic symptom assessment consisted of a 21-item 
questionnaire that evaluated the presence and severity of the following: headache, dizziness, 
nausea, noise sensitivity, light sensitivity, poor concentration, taking longer to think, blurred 
vision, double vision, restlessness, upset stomach, fatigue, sensitive or tender skin, ringing in 
ears, itchy eyes or skin, racing heart, insomnia, hands trembling, feeling faint, abdominal 
pain, diarrhea and constipation. Participants were asked to report the severity of each 
symptom on a 0–10 scale, where 0 represented no problem and 10 represented a major 
problem. Number of somatic symptoms at each timepoint was defined as the number of 
somatic symptoms greater than zero.
 2.5 Statistical analyses
Descriptive and trajectory analyses of extent of pain across time were performed using SAS 
9.3 (SAS Institute, Cary, NC). Descriptive analysis of the whole cohort, after excluding 
previous WP participants, was evaluated. Trajectory analyses were performed using PROC 
TRAJ. This SAS procedure, developed by Jones, Nagin and Roeder, was designed to 
estimate clusters of individuals following similar trends over time[21]. Model fit in TRAJ is 
based on the Bayesian Information Criterion (BIC), a statistic that is similar to adjusted R2 
as it incorporates model complexity and overall fit. BIC value is a fit index used to compare 
competing models that include different numbers or shapes of trajectories. BIC values are 
negative, and in comparing the different models, the best fit model is the one with the 
smallest negative number, closest to 0. To test the inclusion of different numbers of 
trajectories, the estimate of the log Bayes Factor is defined with the following formula: 2loge 
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(B10) ≈ 2(ΔBIC)[21]. The difference is calculated by subtracting the BIC value of the 
simpler model, with a smaller number of trajectories, from the more complex model. 
According to the guidelines, values ranging from 0–2 are interpreted as weak evidence for 
the more complex model, 2 to 6 as moderate evidence, 6–10 as strong and values greater 
than 10 as very strong evidence. The comparisons are completed in a step-wise manner so 
that the two-group model is compared to the one-group, and the three-group model is 
compared to the two-group model. Trajectory membership for each individual was used as 
an identifier, and further descriptive analyses were conducted.
 3. Results
 3.1 Cohort characteristics
A total of 10,629 patients were screened, 1,416 were eligible, 969 consented to study 
participation and 948 completed baseline evaluation. Slightly more than 60% of participants 
were females, more than three quarters had some education past high school, and more than 
half worked full time (Table 1). The median age of study participants was 36 (range 18–65). 
Consistent with eligibility criteria, all participants were discharged to home after ED 
evaluation. Ninety three percent (710/948) of the study participants had musculoskeletal 
strain only, and nearly all participants (939/948, 99%) had an Abbreviated Injury Scale score 
of 1. Fractures were present in 1/948 (<1%, phalanx fracture) participants; a small laceration 
was present in 53/948 (6%) participants. Six week, six month, and one year follow-up 
assessments were completed on 859/948 (91%), 840/948(87%), and 861/948 (91%) of 
enrolled patients, respectively.
 3.2 WP outcomes in the cohort over time
Widespread pain prior to the MVC was reported by 53/948 (6%) of participants; these 
patients were excluded from subsequent analyses. MVC-related WP was present in 238/895 
(27%) at the ED, 160/808 (20%) participants six weeks after MVC, 97/790 (12%) 
participants six months after MVC, and 78/809 (10%) participants one year after MVC.
 3.3 Identifying trajectories of widespread pain development
Fit indices (Table 2) were used to identify the trajectory model for CWP development that 
best corresponded to the data. Bayesian information criterion values identified a two-group 
solution as optimal, with the Bayes Factor value (138) for the two-group linear solution 
indicating very strong model selection [55]. As shown in Table 221.5% of participants were 
classified as having a high probability of a CWP trajectory (“CWP” group), and 78.5% 
participants were classified as having a low probability of a CWP trajectory (“non-CWP” 
group). Demographic characteristics of participants with and without a CWP trajectory are 
shown in Table 1. Those developing CWP after MVC were more likely to be older, female, 
to have a higher BMI, and to have lower educational attainment (Table 1).
 3.4 CWP development after MVC is most consistent with a non-recovery trajectory
Two-group linear solution plots supported a non-recovery model of CWP development 
(Figure 1). More than half of individuals (99/192, 52%) in the CWP group met widespread 
pain criteria in the ED; mean time between MVC and ED presentation among study 
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participants was 1.2 hours. Little change in the probability of widespread pain was observed 
across follow-up time points within the CWP group, indicating little aggregate improvement 
or progression over the course of the year (Fig. 2).
 3.5 Relatively few individuals experienced a substantial increase in number of body 
regions with pain over time
As shown in Figure 3, among individuals with widespread pain one year after MVC, the 
distribution of change in number of body regions between six weeks and one year is 
relatively symmetric around zero (47/78 [60%] had experienced an increase in the number of 
body regions with pain and 31/78 [40%] had experienced no change or a decrease in the 
number of body regions with pain). As shown in Table 3, individuals with a CWP trajectory 
already had substantially more regions of pain than those without a CWP trajectory at the 
time of ED evaluation, and while the number of body regions with pain in the non-CWP 
group steadily declined over time, the number of body regions with pain in the CWP 
trajectory group remained relatively constant. Only 23/78 (30%) of participants meeting 
criteria for CWP at one year had an increase of 4 or more body regions with pain (out of 20 
regions assessed) between six weeks and one year (“spread of pain group”, Fig. 3). The pain 
characteristics in the ED and at week 6 of individuals in the spread of pain group much more 
closely resembled those who consistently had widespread pain across follow-up time points 
than those without widespread pain (Table 4).
 3.6 Somatic symptoms, depressive symptoms, and posttraumatic stress symptoms 
among those in the low vs. high probability of widespread pain groups
Somatic symptoms, depressive symptoms, and posttraumatic stress symptoms among those 
who did and did not develop CWP after MVC are shown in Table 3. Reported depressive 
symptoms during the month prior to MVC were similar in the two groups, but depressive 
symptoms in the widespread pain group at follow up time points were markedly higher. 
Similarly, the number of reported somatic symptoms in the month prior to MVC was similar 
among those who did and did not develop CWP after MVC, but the number of somatic 
symptoms increased markedly among those developing CWP at 6 weeks, 6 months and 1 
year. Individuals developing CWP had greater peritraumatic distress symptoms in the ED 
and greater posttraumatic stress disorder (PTSD) symptoms across follow-up timepoints. At 
six months, 49/170 (29%) of individuals in the CWP group vs. 58/614 (9%) in the non-CWP 
group had substantial PTSD symptoms (χ = 42.42, p < 0.001). At one year, 51/174 (30%) of 
individuals in the CWP group vs. 55/633 (9%) in the non-CWP group had substantial PTSD 
symptoms (χ = 50.87, p < 0.001).
 4. Discussion
The results of this study suggest that the pathogenic trajectory of CWP after MVC is 
characterized by the immediate development of widespread pain which persists, rather than 
the gradual progression of pain from regional to widespread. Approximately 1 in 5 
individuals presenting to the ED after MVC had a CWP trajectory, and there was little 
change in the probability of widespread pain across follow-up time points within this group. 
Similarly, individuals with a CWP trajectory had a high number of body regions with pain in 
JunMei et al. Page 6
Pain. Author manuscript; available in PMC 2017 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the ED which subsequently changed little over time. In addition, among individuals with a 
CWP trajectory the change in number of body regions with pain between six weeks and one 
year after MVC was relatively evenly distributed around zero. A subset of individuals within 
the CWP trajectory group experienced a substantial progression in the number of body 
regions with pain, reporting four or more new body regions with pain at one year compared 
to the six-week timepoint (47/78, [60%]). This data could seem to support a progressive 
onset model of CWP development, however such individuals had pain characteristics in the 
early aftermath of MVC (in the ED in the hours after MVC and at six weeks) that much 
more closely resembled those with CWP than those without CWP.
To our knowledge, the only other study to examine the natural history of CWP after MVC 
was conducted by Holm et al, who examined widespread pain outcomes over time among 
266 individuals who filed an MVC-related insurance claim in the Canadian province of 
Saskatchewan [18]. The design of this study differed markedly from the present study, 
making comparison of study findings difficult. Holm et al designed their study based on the 
accumulation model of CWP development[18], and only individuals completing initial 
insurance claim evaluation with pain limited to a portion of the head, neck, and/or back 
regions were eligible for study participation. Those with more extensive neck or back pain 
(> 5 of 11 areas of pain in these regions) or any pain in a location outside these regions were 
not enrolled[18]. Even among this subset of individuals with limited neck and/or back pain 
in the early aftermath of injury, the investigators still found that CWP most often developed 
before the first follow-up assessment [18]. Of note, only 845/7462 (11%) of those who 
reported locations of body pain on their initial insurance claim had the limited distribution of 
pain required for potential study eligibility. “The others either had different pain patterns or 
already had more widespread pain when making their insurance claim.”[18] We believe that 
these other patterns of pain or more widespread pain among the great majority of individuals 
experiencing MVC are also consistent with a non-recovery model.
Other studies examining the natural history of pain over time in the general population have 
found that the extent of pain exhibits natural variation [4; 37]. Thus, an individual who 
meets criteria for CWP at a follow-up timepoint might not have exceeded the CWP threshold 
if assessed on a different day. However, results of both previous studies and the present study 
indicate that this natural variation occurs across a relatively narrow range. For example, in 
the study of Papgeorgiou et al [37], only 2% of participants without initial pain developed 
CWP over a seven-year follow-up period, and in the present study within-group mean scores 
varied over time but remained distinctly different between groups (Table 3).
Findings of the present study supporting a non-recovery model of CWP development are 
consistent with increasing evidence that pain outcomes after stress exposures such as MVC 
are mediated by central neurobiological mechanisms [2; 6; 8; 30; 32; 33; 43; 44]. This 
evidence includes data that pain in the immediate aftermath of other stressful events such as 
sexual assault is located in many body regions, most of which experienced no tissue trauma, 
and that the distribution of body regions with pain continues to expand in the initial week 
after stress exposure[33]. These data are consistent with evidence that stress exposure can 
result in widespread changes in sensory processing due to mechanisms such as the 
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sensitization of peripheral afferents by persistently elevated levels of catecholamines and 
glucocorticoids[24] and by endogenous opioid-induced hyperalgesia[2; 26].
Results of the present study indicates that older age, female sex, increased BMI, and lower 
educational attainment are associated with vulnerability to CWP are consistent with previous 
studies [3; 15; 20; 35; 45]. Our finding that crash-related factors such as amount of vehicle 
damage showed little association with CWP outcomes is also consistent with previous 
studies[12; 14; 17], as are results of the present study that individuals developing CWP after 
MVC are much more likely to develop substantial co-morbid somatic symptoms, PTSD 
symptoms, and depressive symptoms [7; 13; 31].
CWP is a syndrome defined by the extent/distribution rather than severity of pain, and as 
noted above, has been shown to result in substantial disability and reduced quality of life 
[11; 27]. Extent and severity of pain, both in the present study and in other studies [42], have 
been shown to be only moderately correlated (e.g., correlation between overall pain severity 
and number of body regions with pain in the present study was 0.38 in the ED, 0.53 at week 
6, 0.53 at month 6, and 0.52 at year 1). Biopsychosocial factors contributing to extent vs. 
severity of pain remain poorly understood, and are an important target for future study.
 4.1 Limitations
A number of limitations should be considered when interpreting our results. First, our study 
was limited to individuals who were discharged to home from the ED after evaluation. CWP 
development may differ substantially in those with severe injuries who are admitted to the 
hospital. However, because more than 90% of individuals evaluated in the ED after MVC 
are discharged to home after evaluation[39], and because many individuals who experience 
an MVC do not present to the ED for care[38], we believe the spectrum of injury examined 
in the present study accounts for the great majority of individuals developing CWP. Another 
limitation of the present study is that only European Americans aged 18 to 65 were enrolled. 
Further studies are needed which evaluate the trajectory of CWP development in other 
ethnic groups and in older individuals. Finally, self-report information obtained from study 
participants might have been inaccurate or incomplete. However, baseline data were 
obtained at the time of initial evaluation, 6 weeks prior to the first assessment of persistent 
pain outcomes.
 4.2 Conclusions
Our study results indicate that a non-recovery model most accurately describes the 
pathogenesis of CWP after MVC. Individuals developing CWP after MVC generally have an 
extensive burden of body pain beginning in the immediate aftermath of MVC, which does 
not remit, rather than experiencing a gradual extension of pain from regional to widespread 
over time. As Professor George E. P. Box famously said, “Essentially, all models are wrong, 
but some are useful [9].” We do not believe that a non-recovery model applies to each and 
every individual who ever has or ever will suffer from CWP after MVC. However, our data 
suggest that a non-recovery model is an accurate characterization of CWP in most 
individuals. Future studies evaluating CWP development after stress exposure should begin 
in the early aftermath of the event, so that both non-recovery and accumulation models of 
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pathogenesis can be evaluated. In addition, the results of the present study suggest that 
future preventive intervention studies for this common and morbid outcome might best be 
initiated in the early aftermath of stress exposure, with the goal helping a greater proportion 
of individuals with widespread pain or a high burden of overall body pain transition to 
recovery.
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Fig. 1. 
Candidate trajectory models of widespread pain development after motor vehicle collision 
assessed in the study.
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Fig. 2. 
Trajectory analysis performed using study data indicated that widespread pain after MVC 
develops via non-recovery.
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Fig. 3. 
Change in number of body regions with pain between six weeks and one year after MVC 
among individuals with widespread pain at one year follow-up after MVC. Only 30% of 
individuals experienced an increase of ≥ 4 body regions with pain between these timepoints 
(“spread of pain” group).
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Table 1
Demographic characteristics of all participants, participants with a post-MVC chronic widespread pain 
trajectory, and participants with a non-chronic widespread pain trajectory.a
All Non-widespread pain Widespread pain p-value
Age, mean (SD) 35.4 (13.0) 34.9 (13.0) 37.4 (13.0) 0.02
Female, n (%) 540 (60.3) 411 (59.0) 129 (67.0) 0.02
BMI, mean (SD) 27.6 (6.0) 27.4 (6.0) 28.5 (7.0) 0.03
Education, n (%) 0.02
   High school or less 214 (23.9) 161 (23.0) 53 (28.0)
   Some college or trade school 348 (38.9) 272 (39.0) 76 (39.6)
   College/post-graduate degree 332 (37.1) 269 (38.3) 63 (32.8)
Annual income, n (%) 0.52
   Below $20,000 111 (13.0) 83 (13.3) 28 (16.4)
   $20,000 to $40,000 167 (21.0) 132 (21.1) 35 (20.5)
   $40,000 to $80,000 263 (33.0) 205 (32.7) 58 (33.9)
   >$80,000 256 (32.0) 206 (32.9) 50 (29.2)
Works full time, n (%) 526 (59.0) 415 (59.0) 111 (57.8) 0.41
Damage to vehicle from MVC, n (%)
   None-minor 115 (13.0) 95 (14.0) 20 (10.9) 0.28
   Moderate 269 (31.0) 204 (30.0) 65 (35.5)
   Severe 479 (56.0) 381 (56.0) 98 (53.6)
MVC, motor vehicle collision; BMI, body mass index; SD, standard deviation
a
Trajectories assigned using SAS Procedure PROC TRAJ
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Table 3
Number of body regions with pain, number of somatic symptoms, and depressive and posttraumatic stress 
disorder (PTSD) symptoms in the ED and six weeks, six months, and one year after MVC.
Non-widespread
Pain Trajectory
Widespread
Pain Trajectory
mean (SDd) p-value
Number of body regions with pain
ED 3.7 (3.1) 6.2 (4.0) <0.001
week 6 2.2 (2.6) 7.4 (4.5) <0.001
month 6 1.0 (1.7) 6.2 (4.8) <0.001
year 1 0.8 (1.5) 5.2 (4.4) <0.001
Depressive symptomsa ED 8.6 (0.4) 9.3 (0.7) 0.69
week 6 9.8 (0.6) 21.5 (0.9) <0.001
month 6 9.1 (0.5) 17.8 (0.9) <0.001
year 1 8.7 (0.5) 16.4 (1) <0.001
Number of somatic symptomsb
ED 2.6 (0.1) 2.9 (0.3) 0.23
week 6 5.0 (0.2) 9.5 (0.5) <0.001
month 6 4.5 (0.2) 8.2 (0.5) <0.001
year 1 4.7 (0.2) 8.4 (0.5) <0.001
PTSDc symptoms
ED 17.5 (0.5) 22.5 (0.8) <0.001
week 6 16.5 (0.9) 32.4 (1.5) <0.001
month 6 10.4 (0.8) 25.4 (1.4) <0.001
year 1 9.1 (0.8) 24.3 (1.4) <0.001
aAssessed with Center for Epidemiologic Studies Depression Scale (CES-D).
bAssessed using a 21 item somatic symptom scale.
cAssessed with the Peritraumatic Distress Inventory in the ED, and with Impact of Events Scale Revised (IES-R) at week 6, month 6 and year 1.
dSD, standard deviation
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